Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Apr;29(2):172-182.
doi: 10.1177/15910199221081715. Epub 2022 Mar 3.

Endovascular embolization for the treatment of epistaxis: Systematic review and meta-analysis

Affiliations
Meta-Analysis

Endovascular embolization for the treatment of epistaxis: Systematic review and meta-analysis

Haydn Hoffman et al. Interv Neuroradiol. 2023 Apr.

Abstract

Background: Endovascular embolization (EE) is a treatment option for epistaxis refractory to first-line interventions. Data regarding embolization is limited to small case series and a meta-analysis has not been performed.

Methods: PubMed, Scopus, and EMBASE were used to identify studies that reported outcomes for at least 10 patients undergoing EE for epistaxis. Outcomes included procedural success, rebleeding, and complications. Pooled rates for each outcome were obtained with random effects models.

Results: A total of 44 studies comprising 1664 patients met the inclusion criteria. The mean age ranged from 28.1 to 67 years and there were 28.4% females. The pooled procedural success rate was 87% (95% CI 83.9-89.6, I2 = 53%). Age (OR 0.95, 95% CI 0.91-1) and hereditary hemorrhagic telangiectasia ([HHT], OR 0.97, 95% CI 0.96-0.99) were associated with decreased odds of success. The pooled rebleeding rate was 16.4% (95% CI 13.6-19.6, I2 = 48%), and HHT was associated with greater odds of rebleeding (OR 1.02, 95% CI 1-1.03). The pooled overall complication rate was 14.4% (95% CI 9.8-20.6, I2 = 85.8%). The pooled rates of stroke and vision loss were 2.1% (95% CI 1.5-3.1, I2 = 1.5%) and 1.8% (95% CI 1.2-2.6, I2 = 0%), respectively.

Conclusion: EE for epistaxis has a high rate of procedural success. Interventionalists should be aware of the risk for rebleeding, especially among patients with HHT.

Keywords: Epistaxis; endovascular procedures; therapeutic embolization.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram demonstrating results of the literature review.
Figure 2.
Figure 2.
Forest plot for procedural success showing results from individual studies and the pooled rate calculated from the random effects model.
Figure 3.
Figure 3.
Forest plot for rebleeding rate showing results from individual studies and the pooled rate calculated from the random effects model.
Figure 4.
Figure 4.
Results from the meta-regression demonstrating the effect of hereditary hemorrhagic telangiectasia (HHT) on procedural success and rebleeding.
Figure 5.
Figure 5.
Forest plot for overall complication rate showing results from individual studies and the pooled rate calculated from the random effects model.
Figure 6.
Figure 6.
Funnel plots demonstrating publication bias for procedural success, rebleeding, and complication rates. The funnel plots on the right include imputed missing studies obtained with the trim-and-fill method.
Figure 7.
Figure 7.
Forest plot comparing the procedural success of endovascular embolization to surgical ligation. (EE + : Number of patients who underwent successful endovascular embolization, EE-: Unsuccessful endovascular embolization, S + : Successful surgery, S-: Unsuccessful surgery).

Similar articles

Cited by

References

    1. Koh E, Frazzini NJ K, VI. Epistaxis: vascular anatomy, origins, and endovascular treatment. AJR Am J Roentgenol 2000; 174: 845–851. - PubMed
    1. Manes RP. Evaluating and managing the patient with nosebleeds. Med Clin North Am 2010; 94: 903–912. - PubMed
    1. Parajuli R. Evaluation of etiology and treatment methods for epistaxis: a review at a tertiary care hospital in central Nepal. Int J Otolaryngol 2015; 2015: 283854. - PMC - PubMed
    1. Layton KF, Kallmes DF, Gray LA, et al.Endovascular treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia. AJNR Am J Neuroradiol 2007; 28: 885–888. - PMC - PubMed
    1. Chin CJ, Rotenberg BW, Witterick IJ. Epistaxis in hereditary hemorrhagic telangiectasia: an evidence based review of surgical management. J Otolaryngol Head Neck Surg 2016; 45: 3. - PMC - PubMed

LinkOut - more resources